|
View this as a webpage
September 29, 2025
Moderna’s new RSV product mResvia will be available through the UUAV program on Oct. 1. It is available in pre-filled syringes. Like Arexvy, mResvia is recommended for all adults ages 75 and older and for adults ages 50 to 74 with increased risk of severe respiratory syncytial virus (RSV) disease, but it is not recommended during pregnancy. Abrysvo is the only RSV product recommended during pregnancy.
Penmenvy, GSK’s new MenABCWY (pentavalent meningococcal) vaccine, will be available through the UUAV program starting Oct. 1. It is available in single dose vials.
Pentavalent or MenABCWY vaccines are a combination of MenACWY and MenB vaccines. The pentavalent vaccine can be used when BOTH MenACWY and MenB are due at the same visit. It is an option to reduce the number of injections for healthy people at 16 to 23 years of age when a person’s second MenACWY is due and their first MenB vaccine is recommended after shared clinical decision making. It may also be given when a person is 10 years of age and older and at increased risk for meningococcal disease. It is important to remember that the Men B vaccine series is manufacturer specific and the MenB products are NOT interchangeable.
- If Penbraya (Pfizer’s MenABCWY) was given at 16 years, Trumenba (Pfizer’s MenB) should be given at least 6 months later.
-
If Penmenvy (GSK’s MenABCWY) was used, Bexsero (GSK’s MenB) should be given at least 6 months later.
Sites will now select a MDH vaccine program (e.g., MnVFC or UUAV) when reporting nonviable vaccine in MIIC. Sites should select the program that supplied the nonviable vaccine. This change will help us better manage our vaccine programs and give us more insight into vaccine returns and wastage trends.
The field is on the first screen of “report nonviable vaccine” in MIIC:
- MnVFC Pediatric Vaccines: use to report nonviable vaccine ordered through the MnVFC program.
- UUAV Adult Vaccines: use to report nonviable vaccine ordered through the UUAV program.
- Special vaccine projects (MDH approved): use to report nonviable vaccine ordered for a special project as directed by MDH, such as an outbreak response.
-
Select a vaccine program for every nonviable form in MIIC.
-
Submit separate nonviable forms for MnVFC vaccine and UUAV vaccine.
-
Separate vaccine by program (MnVFC and UUAV) once you have deemed it nonviable. This will make it easier to fill out the form by vaccine program when you are reporting nonviable vaccine.
If you currently have nonviable vaccine that is not separated by vaccine program and you don’t know how to report it in MIIC, reach out to us for guidance.
|
